International Urology and Nephrology

, Volume 37, Issue 3, pp 655–663 | Cite as

Prevention of Nephropathy in Patients with type 2 Diabetes Mellitus

Article

Abstract

The rising incidence of type 2 diabetes mellitus and of its complications will make it the most important health care challenge in the first quarter of the 21st Century. Diabetic nephropathy left unchecked will overwhelm the renal resources. Simple methods (proper diet and exercise, prevention of obesity) are successful in preventing type 2 diabetes in the great majority of the persons at risk. In patients with established type 2 diabetes, nephropathy can be prevented or greatly delayed by strict metabolic control, strict control of blood pressure using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as the first line of drugs, tight control of serum lipids using statins as indicated, low protein diet, avoidance of smoking and other nephrotoxic influences, prevention of abnormalities in calcium/phosphorus metabolism, and prevention of renal anemia by the early use of erythropoietin. Current research offers the promise of definitive prevention of both type 2 diabetes and diabetic nephropathy.

Keywords

Diabetic nephropathy prevention Glycemia Hypertension Lipid metabolism Nephrotoxins Type 2 diabetes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kiberstis, PA 2005A surfeit of subjectsScience307369CrossRefGoogle Scholar
  2. 2.
    Parving, HH, Mauer, M, Ritz, E 2004

    Diabetic nephropathy

    Brenner, BM eds. The Kidney7SaundersPhiladelphia, PA11771818
    Google Scholar
  3. 3.
    Tuomilheto, J, Lindstrom, J, Eriksson, HG,  et al. 2001Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranceN Engl J Med34413431350Google Scholar
  4. 4.
    Knowler, WC, Barrett-Connor, E, Fowler, SE,  et al. 2002Reduction in the incidence of type 2 diabetes with lifestyle interventions or metforminN Engl J Med346393403PubMedGoogle Scholar
  5. 5.
    O’Rahilly, S, Barroso, I, Wareham, NJ 2005Genetic factors in type 2 diabetes: the end of the beginning?Science307370373PubMedGoogle Scholar
  6. 6.
    Paulsen, P, Andersen, G, Genger, M,  et al. 2003Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?Diabetes52194198Google Scholar
  7. 7.
    Kadowaki, T, Hara, K, Yamauchi, T,  et al. 2003Molecular mechanism of insulin resistance and obesityExp Biol Med (Maywood)22811111117Google Scholar
  8. 8.
    Vander Molen, J, Frisse, LM, Fullerton, SM,  et al. 2004Population genetics of CAPN10 and GPR35: implications for the evolution of type 2 diabetes variantsDiabetes5332743285Google Scholar
  9. 9.
    Lazar, MA 2005How obesity causes diabetes: not a tall taleScience307373375CrossRefPubMedGoogle Scholar
  10. 10.
    Schwartz, MW, Porte, D,Jr 2005Diabetes, obesity and the brainScience307375379CrossRefPubMedGoogle Scholar
  11. 11.
    Kahn, SE 2001The importance of β-cell failure in the development and progression of type-2 diabetesJ Clin Endocrinol Metab8640474058PubMedGoogle Scholar
  12. 12.
    Rhodes, CJ 2005Type 2 diabetes – a matter of β-cell life and death?Science307380384CrossRefPubMedGoogle Scholar
  13. 13.
    Lowelll, BB, Shulman, GI 2005Mitochodrial dysfunction and type 2 diabetesScience307384387Google Scholar
  14. 14.
    Fioretto, P, Steffes, MW, Sutherland, DER,  et al. 2998Reversal of lesions of diabetic nephropathy after pancreas transplantationN Engl J Med3396975Google Scholar
  15. 15.
    Pirart, J 1978Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973Diabetes Care1168188Google Scholar
  16. 16.
    Hanssen, KF, Dahl-Jorgensen, K, Lauritzen, T,  et al. 1986Diabetic control and microvascular complicationsDiabetologia29677684CrossRefPubMedGoogle Scholar
  17. 17.
    Ohkubo, Y, Kishikawa, H, Araki, E,  et al. 1995Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year studyDiab Res Clin Pract28103117CrossRefGoogle Scholar
  18. 18.
    UK Prospective Diabetes Study (UKPDS) Group1998Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet352837853Google Scholar
  19. 19.
    Zandi-Nejad, K, Brenner, BM 2005Strategies for renoprotection: 2005Nephrol Rounds (Brigham and Women’s Hospital)315Google Scholar
  20. 20.
    Kassiske, BL, Kalil, R, Ma, JZ,  et al. 1993Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysisAnn Intern Med118129138Google Scholar
  21. 21.
    Ravid, M, Brosh, D, Levi, Z,  et al. 1998Use of enalapril to attenuate decline in renal function in normotensive, microalbuminuric patients with type 2 diabetes mellitusAnn Intern Med128982988PubMedGoogle Scholar
  22. 22.
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators2000Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyLancet355253259Google Scholar
  23. 23.
    Tatti, P, Pahor, M, Byington, RP,  et al. 1998Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDMDiabetes Care21597603PubMedGoogle Scholar
  24. 24.
    UK Prospective Diabetes Study (UKPDS) Group1998Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39BMJ317713720Google Scholar
  25. 25.
    Estasio, RO, Jeffers, BW, Gifford, N, Schrier, RW 2000Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetesDiabetes Care23B54B64Google Scholar
  26. 26.
    Schrier, RW, Estasio, RO, Esler, A, Mehler, P 2002Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokesKidney Int6110861097CrossRefPubMedGoogle Scholar
  27. 27.
    Andersen, AR, Christiansen, JT, Andersen, JK,  et al. 1983Diabetic nephropathy in type 1 (insulin dependent) diabetes: an epidemiological studyDiabetologia25496501CrossRefPubMedGoogle Scholar
  28. 28.
    Norden, G, Nyberg, G 1984Smoking and diabetic nephropathyActa Med Scand215257261PubMedGoogle Scholar
  29. 29.
    Hansen, HP, Tauber-Lassen, E, Jensen, BR, Parving, HH 2002Effect of dietary protein restriction on prognosis in patients with diabetic nephropathyKidney Int62220228CrossRefPubMedGoogle Scholar
  30. 30.
    Gaede, P, Vedel, P, Parving, HH, Pedersen, O 1999Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized studyLancet353617622PubMedCrossRefGoogle Scholar
  31. 31.
    Lewis, EJ, Hunsicker, LG, Bain, RO, Rohde, RD 1993The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathyN Engl J Med32914561462PubMedGoogle Scholar
  32. 32.
    Lewis, EJ, Hunsicker, LG, Clarke, WR,  et al. 2001Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetesN Engl J Med35851860Google Scholar
  33. 33.
    Brenner, BM, Cooper, ME, Zeeuw, D,  et al. 2001Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med345861869CrossRefPubMedGoogle Scholar
  34. 34.
    Parving, HH, Lehnert, H, Brochner-Mortensen, J,  et al. 2001The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med345870878CrossRefPubMedGoogle Scholar
  35. 35.
    Viberti, G, Wheeldon, NM 2002Microalbuminuria reduction in patients with type 2 diabetes mellitus: a blood-pressure independent effectCirculation106672678CrossRefPubMedGoogle Scholar
  36. 36.
    Mogensen, CE, Neldam, S, Tikkanen, I,  et al. 2000Randomized controlled trial of dual blockade of rennin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ314401444Google Scholar
  37. 37.
    Nakao, N, Yoshimura, A, Morita, H,  et al. 2003Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trialLancet361117124PubMedGoogle Scholar
  38. 38.
    Chertow, GM, Burke, SK, Raggi, P 2002Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney Int62245252CrossRefPubMedGoogle Scholar
  39. 39.
    Lau, K 1989Phosphate excess and progressive renal failure: the precipitation-calcification hypothesisKidney Int36918937PubMedGoogle Scholar
  40. 40.
    Gouva, C, Nikolopoulos, P, Ioannidis, JPA, Siamopoulos, KC 2004Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trialKidney Int66753760CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.Sections of Nephrology and General Internal Medicine, Renal Section (111C), New Mexico Veterans Affairs Health Care System and Department of MedicineUniversity of New Mexico School of MedicineAlbuquerqueUSA

Personalised recommendations